Consultant Medical Oncologist
A specialist in "systemic anticancer treatments" and clinical trials for urological cancers including kidney, bladder, testicular and prostate cancer.
Dr Simon Chowdhury was appointed to Guy’s Hospital in 2007 to lead the Medical Oncology group, in the treatment of urological cancers. He also consults at King's and St Thomas’ Hospitals. Simon has recently been appointed chair of the Medical Advisory Committee at Leaders in Oncology Care.
He is a member of the National Cancer Research Institute clinical studies group for prostate cancer. He is also member of the National Cancer Research Institute clinical studies group for metastatic bladder cancer. Dr Chowdhury is the global and national study Chair for several studies investigating ways of improving systemic therapy for urological cancers. Of note, Dr Chowdhury has been chosen to lead STRATOSPHERE – the next large national study for metastatic prostate cancer.
Dr Chowdhury is very actively involved in clinical trial research. He is the lead for urological medical oncology at Guy’s hospital, and the research lead for the treatment of urological cancers within the London Cancer Alliance. He also has a leadership position for urological cancer research at Sarah Cannon Research Institute in London and the United States. He strongly believes in clinical research for both NHS and private patients, and is the global leading recruiter for several studies such as the SPARTAN study in prostate cancer.
Dr Chowdhury has authored over 100 papers on urological cancers in peer-reviewed journals, and has contributed to ten oncology textbooks. He is a member of both the European and American Societies of Oncology and a keen participant in their annual meetings. He is a member of the editorial panel for the British Journal of Urology International. He is actively involved with several charities including sitting on the National Advisory group for Prostate Cancer UK.
Dr Chowdhury received his first degree from the University of Cambridge in 1991 and qualified as a doctor at Guy’s and St Thomas' Medical School in 1994. He completed his PhD in tumour targeting at University College London, and completed training at St George's and The Royal Marsden Hospitals.
He was a visiting Fellow at the Dana Farber Cancer Institute and Harvard Medical School in Boston, with which he retains strong research links. Between 2000 and 2003, Dr Chowdhury was a Research Fellow for Cancer Research UK successfully completing his PhD.
Services provided to HCA
Dr Chowdhury provides medical advisory services for HCA's Harley Street Clinic, Princess Grace Hospital, The Wellington Hospital and Leaders in Oncology Care. In his role, Dr Chowdhury leads interactions with medical staff and the hospital leadership teams to ensure high quality, cost effective care. He helps supervise the oncology resident medical officers (RMO) services across the HCA group for the above hospitals. This ensures high quality day-to-day care for oncology inpatients and those receiving outpatient systemic anti-cancer therapy.
Dr Chowdhury also contributes to the strategy, policies and decision-making regarding oncology treatments and advises HCA to ensure that care provided within these facilities is appropriate and efficient. In his role, Dr Chowdhury advises on initiatives to improve clinical standards by providing professional advice on clinical governance matters and ensuring the adoption of those by colleagues in the oncology area.
In addition, he works with GPs, other members of the urological multi-disciplinary team and patients to educate and advise on relevant clinical updates. He advises on how to improve the patient emergency admission pathway in order to improve patient safety.
For example, recent work has included examining the admission process for oncology patients to ensure that they are reviewed in an appropriate clinical setting.
HCA UK is charged by doctors in return for their expertise and advice, including on how to operate safe hospital facilities delivering complex care. All services provided under this agreement are charged to HCA UK. From January to December 2016, the total charge was £16,029.
HCA requires the doctors that advise us to attest that if they also practice in the NHS that they are not compromising their NHS commitments.
The information disclosed on this page in accordance with the Private Healthcare Market Investigation Order 2014 is true and accurate to the best of HCA’s knowledge and belief.